Mabpharm Ltd is an investment holding company primarily engaged in the research, development and production of monoclonal antibody drugs for cancers and autoimmune diseases. The Companyâ€™s main products include CMAB009 Enlituo (cetuximab Î² injection), CMAB007 Aomaishu (Omalizumab Î± for Injection), CMAB008 Leiting (infliximab for injection) and other products. The Companyâ€™s products are mainly used for colorectal cancer, asthma, urticaria, rheumatoid arthritis, ulcerative colitis in adults and other diseases. The Company is also engaged in the transfer of intellectual property. The Company mainly conducts its business in the domestic market.

Employees

394

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-11-01	HK$0.4350	0.00%	20,000
26-10-30	HK$0.4350	0.00%	0
26-10-29	HK$0.4350	0.00%	72,000
26-10-28	HK$0.4350	0.00%	0
26-10-27	HK$0.4350	-1.14%	102,000

Delayed Quote Hong Kong S.E.

More quotes

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Delayed Hong Kong S.E. 20:41:20 2026-11-01 EST			5-day change	1st Jan Change
0.4350 ^HKD	0.00%		-1.14%	-13.00%

08-28	Mabpharm Limited Reports Earnings Results for the Half Year Ended June 30, 2026	CI
06-24	Mabpharm Limited Receives Approval for New Drug Application of CMAB807X (Denosumab Injection)	CI

Market Cap	1.52B 1.79B 229M 205M 188M 171M 319M 21.71B 325M 2.25B 902M 11.42B 858M 840M 36.02B	P/E 2024	-8.48x	P/E 2025	44.9x
Enterprise Value	1.74B 2.05B 261M 234M 215M 195M 365M 24.82B 371M 2.57B 1.03B 13.05B 981M 960M 41.17B	EV / Sales 2024	5.06x	EV / Sales 2025	3.2x
Free-Float	22.82%	Yield 2024 *	-	Yield 2025	-

08-28	Mabpharm Limited Reports Earnings Results for the Half Year Ended June 30, 2026	CI
06-24	Mabpharm Limited Receives Approval for New Drug Application of CMAB807X (Denosumab Injection)	CI
06-09	Mabpharm Limited Receives Approval For New Drug Application Of CMAB807 Denosumab Injection From National Medical Products Administration	CI
06-09	Mabpharm's Application for Osteoporosis Drug Approved in China	MT
03-26	Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-26	Mabpharm FY profit and total comprehensive income attributable rmb57.1 million	RE
12-05	Mabpharm Limited Announces Change of Address of Principal Place of Business in Hong Kong	CI
25-10-31	Mabpharm Limited Announces Board and Committee Changes, Effective October 31, 2025	CI
25-08-28	Mabpharm Limited Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-03-27	Mabpharm Shrinks Loss by 39% in 2024	MT
25-03-26	Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-01-02	Mabpharm's Infliximab Drug Receives Approval from Pakistan's Drug Regulator	MT
25-01-02	Mabpharm Limited Announces Approval from the Drug Regulatory Authority of Pakistan on the Registration of Core Product, CMAB008 (Infliximab for Injection)	CI

23-11-13	Cryopyrin-Associated Periodic Syndrome Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	AQ
21-07-20	Mabpharm : Sorrento Announces Its Partner Mabpharm Has Received Marketing Approval In China For Infliximab Biobetter	AQ
21-04-30	Mabpharm : POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON FRIDAY, APRIL 30, 2021	PU
21-04-21	Mabpharm : FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, JUNE 18, 2021	PU
21-04-12	Mabpharm : (1) DISCLOSEABLE AND CONNECTED TRANSACTION IN RELATION TO THE ACQUISITION OF CMAB807 (2) CONTINUING CONNECTED TRANSACTIONS IN RELATION TO THE CLINICAL TRIALS AGREEMENT AND THE CDMO AGREEMENT AND (3) NOTICE OF EXTRAORDINARY GENERAL MEETING	PU

Mabpharm Limited Stock

Stocks

2181

KYG5780F1046

Biotechnology & Medical Research

Valuation: Mabpharm Limited

Chart: Mabpharm Limited

Latest news: Mabpharm Limited

Press Releases: Mabpharm Limited

Quotes and Performance

Price Extremes

Managers and Directors: Mabpharm Limited

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

1 week	-1.14%
1 month	-11.22%
3 months	+8.75%
6 months	-3.33%
Current year	-13.00%

1 week	0.42	0.44
1 month	0.42	0.55
Current year	0.31	0.81
1 year	0.31	0.81
3 years	0.25	0.94
5 years	0.25	1.2
10 years	0.25	1.8

Manager	Title	Age	Since
Hao Wang CEO	Chief Executive Officer	57	2020-10-27
Sheng Hou PRN	Corporate Officer/Principal	49	2023-11-30
Jing Tao PRN	Corporate Officer/Principal	53	2018-08-02

Director	Title	Age	Since
Hao Wang BRD	Director/Board Member	57	2018-07-19
Yun Feng Li BRD	Director/Board Member	49	2018-07-19
Shu Ge Jiao CHM	Chairman	60	2018-07-19

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MABPHARM LIMITED	0.00%	-1.14%	-16.35%	-5.43%	229M
WUXI APPTEC CO., LTD.	-0.62%	-1.87%	+42.87%	+67.17%	63.77B
ARGENX SE	+0.35%	+3.20%	+14.40%	+73.89%	56.37B
LONZA GROUP AG	+0.53%	+1.96%	+16.24%	+102.20%	54.62B
IQVIA HOLDINGS INC.	-2.81%	-4.31%	+23.50%	+48.51%	44.06B
BEONE MEDICINES AG	-0.33%	-1.93%	+19.28%	+104.26%	42.11B
REVOLUTION MEDICINES, INC.	+0.55%	+2.31%	+225.14%	+840.10%	41B
GENMAB A/S	+3.27%	+47.96%	+112.84%	+91.02%	34.92B
CELLTRION, INC.	+1.22%	-1.44%	+14.57%	+47.05%	32.82B
INSMED INCORPORATED	+0.89%	+20.55%	-40.62%	+350.50%	24.7B
Average	+0.31%	+6.24%	+41.19%	+171.93%	39.46B
Weighted average by Cap.	+0.18%	+5.44%	+47.95%	+173.31%

	2024	2025
Net sales	258M 304M 38.8M 34.75M 31.96M 28.96M 54.13M 3.68B 55.15M 381M 153M 1.94B 146M 143M 6.11B	646M 762M 97.07M 86.94M 79.97M 72.46M 135M 9.22B 138M 954M 383M 4.85B 364M 357M 15.29B
Net income	-128M -151M -19.22M -17.22M -15.84M -14.35M -26.82M -1.83B -27.32M -189M -75.81M -960M -72.14M -70.61M -3.03B	57.13M 67.34M 8.58M 7.69M 7.07M 6.41M 11.98M 815M 12.2M 84.33M 33.85M 429M 32.21M 31.53M 1.35B
Net Debt	222M 262M 33.39M 29.91M 27.51M 24.92M 46.59M 3.17B 47.46M 328M 132M 1.67B 125M 123M 5.26B	217M 256M 32.68M 29.26M 26.92M 24.39M 45.59M 3.1B 46.44M 321M 129M 1.63B 123M 120M 5.15B